Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -375.69% is 258% below its 5-year average of -104.90%, near the high end of its 5-year range (-4405.15%–-43.68%).
79.50% above its 12-month average of -1832.44%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -764.46%.
EBITDA MARGIN
-375.69%
EBITDA MARGIN AVG TTM
-1832.44%
EBITDA MARGIN AVG 3Y
-319.14%
EBITDA MARGIN AVG 5Y
-104.90%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+79.50%
CURRENT VS 3Y AVG
-17.72%
CURRENT VS 5Y AVG
-258.14%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
iSpecimen Inc.
Market Cap
$2.64M
EBITDA Margin
-375.69%
TTM Avg
-1832.44%
3Y Avg
-319.14%
5Y Avg
-104.90%
Market Cap
$2.62M
EBITDA Margin
-129.25%
TTM Avg
-125.71%
3Y Avg
-160.72%
5Y Avg
-184.50%
Market Cap
$2.57M
EBITDA Margin
-372.74%
TTM Avg
-308.17%
3Y Avg
-306.11%
5Y Avg
-396.88%
Market Cap
$2.55M
EBITDA Margin
-163.38%
TTM Avg
-126.27%
3Y Avg
-20964.27%
5Y Avg
-20964.27%
Market Cap
$2.52M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.36M
EBITDA Margin
-776.30%
TTM Avg
-1492.64%
3Y Avg
-21514.87%
5Y Avg
-21514.87%
Market Cap
$2.32M
EBITDA Margin
-100324.78%
TTM Avg
-75768.79%
3Y Avg
-56097.78%
5Y Avg
-38080.91%
Market Cap
$3.00M
EBITDA Margin
-22711.52%
TTM Avg
-15924.10%
3Y Avg
-12940.13%
5Y Avg
-12940.13%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iSpecimen Inc. (ISPC) | $2.64M | -375.69% | -1832.44% | -319.14% | -104.90% |
| Nuwellis, Inc. (NUWE)vs › | $2.62M | -129.25% | -125.71% | -160.72% | -184.50% |
| Jaguar Health, Inc. (JAGX)vs › | $2.57M | -372.74% | -308.17% | -306.11% | -396.88% |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.55M | -163.38% | -126.27% | -20964.27% | -20964.27% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.52M | N/A | N/A | N/A | N/A |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.45M | N/A | N/A | N/A | N/A |
| Onconetix, Inc. (ONCO)vs › | $2.36M | -776.30% | -1492.64% | -21514.87% | -21514.87% |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | -100324.78% | -75768.79% | -56097.78% | -38080.91% |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.00M | -22711.52% | -15924.10% | -12940.13% | -12940.13% |
| Revelation Biosciences, Inc. (REVB)vs › | $3.04M | N/A | N/A | N/A | N/A |
Gross Margin
1.3%
EBITDA Margin
-375.7%
Operating Margin
-465.4%
Net Margin
-2449.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -764.46% |
| 2026-03-31 | -1539.95% |
| 2025-12-31 | -4405.15% |
| 2025-09-30 | -2257.90% |
| 2025-06-30 | -194.73% |
| 2025-03-31 | -114.01% |
| 2024-12-31 | -358.68% |
| 2024-09-30 | -43.68% |
| 2024-06-30 | -55.00% |
| 2024-03-31 | -104.97% |
| 2023-12-31 | -88.95% |
| 2023-09-30 | -60.12% |
| 2023-06-30 | -186.03% |
| 2023-03-31 | -70.18% |
| 2022-12-31 | -59.96% |
| 2022-09-30 | -108.54% |
| 2022-06-30 | -98.93% |
| 2022-03-31 | -82.88% |
| 2021-12-31 | -68.21% |
| 2021-09-30 | -44.33% |
| 2021-06-30 | -44.12% |
| 2021-03-31 | -23.49% |
| 2020-12-31 | -27.51% |
| 2020-09-30 | -23.95% |
| 2020-06-30 | -5.11% |
| 2020-03-31 | -13.13% |
| 2019-12-31 | -43.25% |
| 2019-09-30 | -219.17% |
